This activity was originally presented at the 2023 Asembia Specialty Pharmacy Summit.
Program Description
Primary immunodeficiency disorders (PIDDs) refer to a large heterogeneous group of disorders that result from defects in the development of the immune system and/or function. Timely diagnosis and early treatment interventions are important to alleviate associated complications as well as the health and economic burdens of PIDDs. Immunoglobulin (Ig) replacement has been the backbone of therapy for patients with PIDDs. Intravenous Ig has been routinely used, and the use of subcutaneous Ig is increasing due to flexibility and reduced adverse effects and infusion time. Another important discussion for Ig therapy is the potential convenience of self-administration. Specialty pharmacists must be familiar with the most up-to-date information about intravenous and subcutaneous Ig administration, be able to identify patients who are ideal candidates for one route versus another, and ensure patients are properly educated regarding administration and intervention strategies to improve adherence and quality of life. Through this activity, pharmacists will be equipped to make patient-specific product recommendations, implement shared decision making into treatment planning and management, and educate patients and caregivers about treatment expectations.
Target audience: Specialty pharmacists
Type of activity: Application
Release date: May 17, 2023
Expiration date: May 17, 2024
Time to complete activity: 1.5 hours
Learner level: Foundational
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Determine the clinical burden and quality of life impact of primary immunodeficiency disorder (PIDD) and the role of intravenous (IV) and subcutaneous (SC) immunoglobulin (Ig)
- Examine efficacy and safety data of IVIg and SCIg, as well as differences in administration, dosing, time between infusions, and common adverse effects
- Identify opportunities for pharmacists to improve patient management, coordination of care, and access to treatments for PIDD to reduce the clinical and economic burden
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
